NASDAQ:ANIK - Anika Therapeutics Stock Price, Price Target & More

$45.13 -0.40 (-0.88 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$45.13
Today's Range$45.03 - $46.17
52-Week Range$42.51 - $69.81
Volume88,851 shs
Average Volume88,919 shs
Market Capitalization$671.35 million
P/E Ratio23.03
Dividend YieldN/A
Beta1.73

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Debt-to-Equity RatioN/A
Current Ratio15.79%
Quick Ratio14.10%

Price-To-Earnings

Trailing P/E Ratio23.03
Forward P/E Ratio28.75
P/E Growth2.9

Sales & Book Value

Annual Sales$113.42 million
Price / Sales5.87
Cash Flow$2.2851 per share
Price / Cash19.75
Book Value$17.97 per share
Price / Book2.51

Profitability

EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins28.05%
Return on Equity11.91%
Return on Assets11.05%

Miscellaneous

Employees123
Outstanding Shares14,740,000

How to Become a New Pot Stock Millionaire

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.41 by $0.03. The biotechnology company earned $29.39 million during the quarter, compared to analyst estimates of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. Anika Therapeutics's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.54 EPS. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

3 brokerages have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $57.00 to $68.00. On average, they expect Anika Therapeutics' stock price to reach $62.50 in the next twelve months. View Analyst Ratings for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Joseph G. Darling, President, Chief Executive Officer, Director (Age 59)
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary (Age 42)
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer (Age 45)
  • Richard Hague, Chief Commercial Officer (Age 57)
  • Joseph Lyon Bower Ph.D., Lead Independent Director (Age 79)
  • Raymond J. Land, Independent Director (Age 72)
  • Glenn R. Larsen Ph.D., Independent Director (Age 62)
  • Jeffrey S. Thompson, Independent Director (Age 51)
  • Steven E. Wheeler, Independent Director (Age 70)

Has Anika Therapeutics been receiving favorable news coverage?

Media headlines about ANIK stock have trended positive this week, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.41 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SHERWOOD CHARLES H (5.15%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $45.13.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $671.35 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anika Therapeutics (NASDAQ:ANIK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Anika Therapeutics in the last 12 months. Their average twelve-month price target is $62.50, suggesting that the stock has a possible upside of 38.49%. The high price target for ANIK is $68.00 and the low price target for ANIK is $57.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.672.673.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.50$62.50$57.00N/A
Price Target Upside: 38.49% upside8.30% upside6.76% upsideN/A

Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History

Price Target History for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Barrington ResearchDowngradeOutperform -> Market PerformHighView Rating Details
1/26/2018SidotiInitiated CoverageBuyLowView Rating Details
1/24/2018First AnalysisUpgradeEqual Weight -> Overweight$45.00 -> $68.00HighView Rating Details
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Anika Therapeutics (NASDAQ:ANIK) Earnings History and Estimates Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Earnings Estimates

2018 EPS Consensus Estimate: $1.57
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.24$0.26$0.25
Q2 20182$0.41$0.44$0.43
Q3 20182$0.37$0.41$0.39
Q4 20182$0.50$0.51$0.51

Anika Therapeutics (NASDAQ ANIK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.32N/AView Earnings Details
2/21/2018Q4 2017$0.41$0.38$29.85 million$29.39 millionViewListenView Earnings Details
10/25/2017Q3 2017$0.41$0.46$27.44 million$27.18 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.44$0.7560$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.3750$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.17$0.21$15.54 million$15.25 millionViewN/AView Earnings Details
2/27/2013Q4 2012$0.23$0.42ViewN/AView Earnings Details
10/30/2012Q3 2012$0.16$0.11ViewN/AView Earnings Details
8/1/2012Q2 2012$0.26ViewN/AView Earnings Details
5/3/2012Q1 2012$0.14ViewN/AView Earnings Details
2/29/2012Q4 2011$0.21ViewN/AView Earnings Details
11/2/2011Q3 2011$0.22ViewN/AView Earnings Details
8/4/2011Q2 2011$0.17ViewN/AView Earnings Details
5/4/2011Q1 2011$0.02ViewN/AView Earnings Details
3/9/2011Q4 2010$0.10ViewN/AView Earnings Details
11/8/2010Q3 2010$0.09ViewN/AView Earnings Details
8/9/2010Q2 2010$0.08ViewN/AView Earnings Details
5/10/2010Q1 2010$0.05ViewN/AView Earnings Details
3/16/2010Q4 2009$0.17ViewN/AView Earnings Details
10/27/2009Q3 2009$0.10$0.13ViewN/AView Earnings Details
7/22/2009Q2 2009$0.08$0.08ViewN/AView Earnings Details
4/28/2009Q1 2009$0.09$0.05ViewN/AView Earnings Details
3/5/2009Q4 2008$0.13$0.10ViewN/AView Earnings Details
11/3/2008Q3 2008$0.12$0.10ViewN/AView Earnings Details
7/22/2008Q2 2008$0.05$0.07ViewN/AView Earnings Details
4/30/2008Q1 2008$0.08$0.05ViewN/AView Earnings Details
3/5/2008Q4 2007$0.13$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Anika Therapeutics (NASDAQ:ANIK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.10%
Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Richard HagueInsiderSell5,250$54.48$286,020.00View SEC Filing  
10/23/2017Charles H SherwoodCEOSell22,228$60.06$1,335,013.68158,297View SEC Filing  
10/20/2017Charles H SherwoodCEOSell5,991$60.04$359,699.64158,297View SEC Filing  
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21174,705View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03246,740View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.7515,845View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.6038,513View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.9014,165View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anika Therapeutics (NASDAQ ANIK) News Headlines

Source:
DateHeadline
Anika Therapeutics (ANIK) Downgraded to Sell at BidaskClubAnika Therapeutics (ANIK) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM
Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
finance.yahoo.com - April 18 at 5:32 PM
Anika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by AnalystsAnika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 11:20 PM
Anika Therapeutics (ANIK) Downgraded by ValuEngineAnika Therapeutics (ANIK) Downgraded by ValuEngine
www.americanbankingnews.com - April 12 at 10:19 PM
Anika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClubAnika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 12 at 7:25 PM
Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair SocietyAnika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
finance.yahoo.com - April 6 at 8:46 AM
Brokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per ShareBrokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per Share
www.americanbankingnews.com - March 30 at 3:24 AM
With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?
finance.yahoo.com - March 29 at 8:44 AM
 Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 26 at 1:32 AM
Edited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMTEdited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMT
finance.yahoo.com - March 22 at 5:24 PM
 Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK) Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 20 at 1:18 AM
Directors Letter Micro Cap Summary - March 2018Director's Letter Micro Cap Summary - March 2018
seekingalpha.com - March 15 at 5:53 PM
Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual MeetingAnika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
finance.yahoo.com - March 14 at 8:58 AM
Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - March 10 at 12:17 PM
Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM
Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM
 Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK) Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 5 at 5:14 AM
Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.
www.americanbankingnews.com - March 1 at 4:56 AM
First Analysis Comments on Anika Therapeutics Incs FY2019 Earnings (ANIK)First Analysis Comments on Anika Therapeutics Inc's FY2019 Earnings (ANIK)
www.americanbankingnews.com - February 28 at 3:18 PM
First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 27 at 8:38 AM
New Strong Sell Stocks for February 27thNew Strong Sell Stocks for February 27th
finance.yahoo.com - February 27 at 8:37 AM
Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 8:37 AM
Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 26 at 5:24 PM
Equities Analysts Issue Forecasts for Anika Therapeutics Incs Q1 2018 Earnings (ANIK)Equities Analysts Issue Forecasts for Anika Therapeutics Inc's Q1 2018 Earnings (ANIK)
www.americanbankingnews.com - February 26 at 3:18 AM
Anika Therapeutics (ANIK) Lowered to Hold at BidaskClubAnika Therapeutics (ANIK) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM
Anika Therapeutics (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAnika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 24 at 8:30 AM
Anika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - BenzingaAnika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - Benzinga
www.benzinga.com - February 24 at 8:30 AM
Kamada (KMDA) and Anika Therapeutics (ANIK) Critical SurveyKamada (KMDA) and Anika Therapeutics (ANIK) Critical Survey
www.americanbankingnews.com - February 24 at 1:06 AM
Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In DowngradeAnika Therapeutics Shares Stunted By Increased Investment, Barrington Says In Downgrade
finance.yahoo.com - February 23 at 5:42 PM
Anika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington ResearchAnika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington Research
www.americanbankingnews.com - February 23 at 4:28 PM
Anika Therapeutics Inc. 2017 Q4 - Results - Earnings Call SlidesAnika Therapeutics Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 5:27 PM
Anika Therapeutics (ANIK) Releases  Earnings Results, Misses Expectations By $0.03 EPSAnika Therapeutics (ANIK) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - February 22 at 3:26 PM
Anika Reports Fourth Quarter and Full Year 2017 Financial ResultsAnika Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 21 at 5:17 PM
When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?
finance.yahoo.com - February 21 at 5:17 PM
Zacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 3:14 AM
Anika Therapeutics (ANIK) Set to Announce Earnings on WednesdayAnika Therapeutics (ANIK) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 4:32 AM
Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
finance.yahoo.com - February 8 at 8:21 AM
Anika Therapeutics (ANIK) to Release Earnings on TuesdayAnika Therapeutics (ANIK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM
 Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK) Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 3 at 3:26 AM
Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for OsteoarthritisAnika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
finance.yahoo.com - February 2 at 9:46 AM
First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"
www.americanbankingnews.com - January 28 at 6:36 PM
Anika Therapeutics (ANIK) Lifted to Buy at BidaskClubAnika Therapeutics (ANIK) Lifted to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 10:16 AM
Sidoti Initiates Coverage on Anika Therapeutics (ANIK)Sidoti Initiates Coverage on Anika Therapeutics (ANIK)
www.americanbankingnews.com - January 26 at 4:54 PM
First Analysis Weighs in on Anika Therapeutics Incs Q4 2017 Earnings (ANIK)First Analysis Weighs in on Anika Therapeutics Inc's Q4 2017 Earnings (ANIK)
www.americanbankingnews.com - January 26 at 6:46 AM
Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid ArthritisAnika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
finance.yahoo.com - January 25 at 9:46 AM
First Analysis Weighs in on Anika Therapeutics Incs FY2017 Earnings (ANIK)First Analysis Weighs in on Anika Therapeutics Inc's FY2017 Earnings (ANIK)
www.americanbankingnews.com - January 25 at 7:58 AM
Recent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 22 at 9:22 AM
 Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK) Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - January 19 at 3:58 AM
Anika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head AnalysisAnika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head Analysis
www.americanbankingnews.com - January 6 at 1:36 PM
 Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 4 at 2:00 AM

SEC Filings

Anika Therapeutics (NASDAQ:ANIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anika Therapeutics (NASDAQ ANIK) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.